Bladder News and Research

RSS

Genetic factors can explain people's susceptibility to urinary incontinence

Much of the risk of developing incontinence before middle age is determined by our genes. Genetic factors can explain half of people's susceptibility to urinary incontinence, a study of twins at the University of Gothenburg and Karolinska Institutet reveals.

5 Apr 2011

Study: Diabetes is linked with risk of cancer and mortality

Results of the NIH-AARP Diet and Health Study revealed that diabetes is associated with lower risk of prostate cancer in men but with higher risk of other cancers in both men and women.

4 Apr 2011

Common genetic variation linked to bladder cancer risk and telomere length

A common genetic variation links to both bladder cancer risk and to the length of protective caps found on the ends of chromosomes, scientists at The University of Texas MD Anderson Cancer Center reported today at the AACR 102nd Annual Meeting.

4 Apr 2011

FDA approves Medtronic's InterStim Therapy to improve bowel control

Medtronic, Inc. today announced U.S. Food and Drug Administration approval of InterStim Therapy for Bowel Control. InterStim Therapy, previously available to treat the symptoms of overactive bladder and non-obstructive urinary retention, is now also approved for the treatment of chronic fecal incontinence in patients who have failed or are not candidates for more conservative treatments.

1 Apr 2011

Prostatic artery embolization comparable to transurethral resection

A new interventional radiology treatment that blocks blood supply to men's enlarged prostate glands shows comparable clinical results to transurethral resection of the prostate (or TURP), considered the gold standard (or most common) treatment. However, this minimally invasive treatment-prostatic artery embolization-has none of the risks associated with TURP, such as sexual dysfunction, urinary incontinence, blood loss and retrograde ejaculation, noted researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago.

30 Mar 2011

Uterine fibroid embolization reduces fibroid-related urinary symptoms

Uterine fibroid embolization—an interventional radiology treatment for the noncancerous yet very common growths that develop in the muscular wall of the uterus—improves a number of women's lower urinary tract problems that are specifically caused by those fibroids, confirm researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago, Ill.

30 Mar 2011

Study: Marijuana use may affect cognitive skills in patients with MS

Any possible pain relief that marijuana has for people with multiple sclerosis may be outweighed by the drug's apparent negative effect on thinking skills, according to research published in the March 29, 2011, print issue of Neurology, the medical journal of the American Academy of Neurology.

29 Mar 2011

Researchers identify new mechanism underlying MS

Multiple sclerosis is a disabling autoimmune disease in which nerve fibers are attacked by the patient's own immune system. Researchers at Ludwig-Maximilians-Universitaet in Munich have identified a new mechanism that contributes to nerve fiber damage - and shown that this damage can be reversed.

28 Mar 2011

German company steps up production of Radiogardase following Japan nuclear crisis

Heyltex Corporation is the exclusive U.S. distributor of Radiogardase® (Prussian Blue insoluble capsules), the only FDA-approved drug to treat people who have been internally contaminated with radioactive cesium (Cs-137), which is manufactured by Heyl chem. pharm. Fabrik Berlin GmbH in Germany.

25 Mar 2011

Tengion 2010 adjusted net loss decreases to $25.8 million

Tengion, Inc. today provided a business update and reported its financial results for the year ended December 31, 2010.

25 Mar 2011

Emory plays key role in bringing advanced proton cancer therapy to Georgia

Emory Healthcare is a key player in plans to bring the world's most advanced radiation treatment for cancer patients to Georgia. In furtherance of that role, Emory Healthcare has signed a letter of intent with Advanced Particle Therapy, LLC, of Minden, Nevada, opening the door to a final exploratory phase for development of The Georgia Proton Treatment Center - Georgia's first proton therapy facility.

25 Mar 2011

AltheRx purchases all assets related to Solabegron from GlaxoSmithKline

AltheRx Inc., a privately-held clinical development company, announced today that it has purchased all assets related to Solabegron from GlaxoSmithKline. Solabegron is a highly selective and potent beta3-adrenoceptor agonist that has demonstrated positive results in Phase II clinical programs for the treatment of Overactive Bladder in women and Irritable Bowel Syndrome.

25 Mar 2011

New study: Prostate and breast cancer usually recur in bone

Like bad neighbors who decide to go wreck another community, prostate and breast cancer usually recur in the bone, according to a new University of Michigan study.

24 Mar 2011

MnSOD oral drug can protect against lung cancer radiation therapy

Patients with advanced non-small cell lung cancer can safely take an experimental oral drug intended to protect healthy tissue from the effects of radiation, according to a study led by researchers at the University of Pittsburgh Cancer Institute and published in this month's issue of Human Gene Therapy.

23 Mar 2011

NeoTract initiates patient enrollment for UroLift System trial to treat prostrate cancer

NeoTract, Inc. a medical device company focused on developing urology devices, today announced that the first U.S. patients have been enrolled in a multinational trial of its UroLift® System at Western Urological Clinic in Salt Lake City, Utah.

23 Mar 2011

Astellas announces positive results from mirabegron phase III trials against OAB

Astellas Pharma Inc. today announced the results of two pivotal phase III clinical trials for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder, show mirabegron significantly improves key OAB symptoms - urinary incontinence and frequency of micturition.

23 Mar 2011

Positive results from TheraVida THVD-201 Phase 1 trial in patients with OAB, UUI

TheraVida, Inc., a clinical stage biopharmaceutical company developing novel combination drug products, today presented positive results from a Phase 1 clinical trial of its lead product candidate THVD-201 for the treatment of overactive bladder and urge urinary incontinence.

23 Mar 2011

Patients with bone cancer can benefit from radical surgery

During a radical surgery to treat a rare bone cancer, surgeons at UC San Diego Health System and Moores Cancer Center removed 50 percent of a patient's pelvis. Instead of amputating the connected leg, the surgical team, comprised of orthopaedic, vascular and urologic experts, saved the entire limb. The patient was able to walk with assistance five weeks after surgery.

22 Mar 2011

Scientists create new drug delivery system to treat cancer

Scientists in Syracuse University's Chemistry Department have created a new drug delivery system expected to advance the effectiveness of cancer-killing drugs. It uses gold nanoparticles with attached DNA that binds to a proven anti-cancer drug, Doxorubicin or DOX.

16 Mar 2011

NAFC honors Florida's Cleveland Clinic physician with Continence Care Champion Award

The National Association For Continence awarded Gamal Ghoniem, MD, with the Rodney Appell Continence Care Champion Award at the Society for Urodynamics and Female Urology Awards Reception on March 4, held during the 2011 SUFU Winter Meeting in Phoenix, AZ.

16 Mar 2011